An anti-IL-2 antibody increases serum halflife and improves anti-tumor efficacy of human recombinant interleukin-2
Authors:
- Julia L. PhelpsJPJulia L. Phelps
- Linda M. KaravodinLKLinda M. Karavodin
- 1 November 1994
- journal article
- Published by Elsevier in Immunopharmacology
- Vol. 28 (3) , 223-232
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Enhancement of anti-tumor activity of recombinant interleukin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2Biotherapy, 1993
- T-cell growth factors and the treatment of patients with cancerClinical Immunology and Immunopathology, 1992
- Cytokine modulation of cell growth and role in tumour therapyEuropean Journal of Cancer, 1992
- Intratumoral low-dose interleukin-2 induces rejection of distant solid tumourCancer Immunology, Immunotherapy, 1991
- The Current Use of Interferons, Interleukin-2 and Tumor Necrosis Factor in Renal Cell CancerUrologia Internationalis, 1991
- Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. phenotypic and functional analysis of the peripheral blood mononuclear cellsCancer Immunology, Immunotherapy, 1990
- Antitumor effect of combination of murine recombinant interferon β, murine recombinant interferon γ and human recombinant interleukin-2 in MethA-bearing miceCancer Immunology, Immunotherapy, 1990
- Autoantibodies to cytokines - friends or foes?Immunology Today, 1990
- An explanation of the variable clinical response to interleukin 2 and LAK cellsImmunology Today, 1990
- Interleukin 2: the molecule and its functionImmunology Today, 1984